Average mean decrease Gini across 100 partitions for the top 10 most important variables for binary mixed model and random forest. by Helal El-Zaatari (20442243)

Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

Soft phyllite specimens at different degrees of weathering: (a) strongly weathered; (b) weakly weathered; (c) slightly weathered. by Hong Zhang (25820)

Subjects:

Bar chart showing the mean age at first menstruation across Indian states for the years 1992–93 and 2019–21. by MD. Nahid Hassan Nishan (22264861)

Subjects:

Middle cerebral artery mean flow velocity at three time points. by Marco Carbonara (11483575)

Subjects:

PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. by Katherine Schubert (5452712)

The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Overall and sex-stratified paroxysmal tachycardia-related age-adjusted mortality rates per 100,000 in adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

S1 Graphical abstract - by Aman Goyal (19231397)

Subjects:

Paroxysmal tachycardia-related age-adjusted mortality rates per 100,000, stratified by census regions in adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Paroxysmal tachycardia-related age-adjusted mortality rates per 100,000 in adults in the metropolitan and non-metropolitan areas in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Paroxysmal tachycardia-related age-adjusted mortality rates per 100,000, stratified by race in adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Paroxysmal tachycardia-related age-adjusted mortality rates per 100,000, stratified by age groups in adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Paroxysmal tachycardia-related deaths and age-adjusted mortality rates per 100,000, stratified by state in adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects: